# 9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Source: https://onco.cc/trials/nct06823427/  
OnCo record `nct06823427` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.

## Summary

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma is a phase 2 interventional study registered as NCT06823427 by Mabwell (Shanghai) Bioscience Co., Ltd., with 60 participants planned, started 2025-01-17 and due to reach its primary completion in 2026-06. Interventions recorded: 9MW2821 and Toripalimab (JS001 ).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06823427
- Phase: 2
- Setting: A Randomized Phase II Trial to Evaluate 9MW2821 in Combination With Toripalimab Compared With 9MW2821 Monotherapy for the 1st Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
- Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06823427: https://clinicaltrials.gov/study/NCT06823427

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Toripalimab](https://onco.cc/drugs/toripalimab/)

---
JSON: https://onco.cc/api/v1/entities/nct06823427.json